Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association - 1 Jan 2018

Iyer Priyanka C, Dadu Ramona, Ferrarotto Renata, Busaidy Naifa L, Habra Mouhammed A, Zafereo Mark, Gross Neil, Hess Kenneth R, Gule-Monroe Maria, Williams Michelle D, Cabanillas Maria E

Abstract excerpt

BACKGROUND: Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis, despite systemic cytotoxic chemotherapy. The objective of this study was to investigate the efficacy and safety of targeted therapy in ATC patients when used outside of a clinical trial. METHODS: This is a retrospective review from April 2015 to May 2016 at a single academic institution where 16 ATC patients receiving targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to Oximes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenylurea Compounds

Share to Progression-Free Survival

Share to Pyridones

Share to Pyrimidinones

Share to Quinolines

Share to Thyroid Carcinoma, Anaplastic

Source

Open in PubMed Open full text

Identifiers

PMID: 29161986
DOI: 10.1089/thy.2017.0285
PMCID: PMC6425981

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.PMID 29161986Read ↗

Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity Read ↗

Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.Semantic proximity Read ↗

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read ↗

Evaluating new treatments for anaplastic thyroid cancer.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.Semantic proximity Read ↗

Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience.Semantic proximity Read ↗

Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancerSemantic proximity Read ↗

Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.Semantic proximity Read ↗

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.